RxNews Recap for Tuesday 12-22-09 Print E-mail
By Mary Davila   
Tuesday, 22 December 2009 19:17

Below is a list of the companies that made news in the healthcare sector on Tuesday, December 22, 2009.

Biotech investors interested in seeing more details about these companies and a full list of their related stories can do so by typing the stock ticker symbol into the Stock Quotes box on the right side of the page.

Advaxis, Inc., (OTCBB: ADXS), the live, attenuated Listeria monocytogenes (Lm) biotechnology company, has been invited to present at the Biotech Showcase Conference, January 12-13 at the Marines' Memorial Club & Hotel in San Francisco.

ARCA biopharma, Inc. (Nasdaq: ABIO) today announced that it has submitted a study protocol for review under the U.S. Food and Drug Administration’s (FDA) Special Protocol Assessment (SPA) process for the design of a clinical trial to assess the safety and efficacy of GencaroTM, in approximately 3,000 patients with chronic heart failure who have the genotype that appears to respond most favorably to Gencaro.

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that it has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for lorcaserin, Arena's internally discovered and developed drug candidate for weight management, including weight loss and maintenance of weight loss.

Cleveland BioLabs, Inc. (NASDAQ: CBLI) today issued a statement from its President and CEO, Michael Fonstein, Ph.D., providing an update on clinical and corporate developments of the past year. The statement is included in its entirety below:  "As we close 2009, I would like to take this opportunity to reflect upon some of our accomplishments and update you on our overall progress.

CTD Holdings, Inc. (OTCBB: CTDH) (FRANKFURT: CDJ) announced today that the Company has entered into a Letter of Intent to form a Joint Venture with J. Jireh Holdings, LLC.

Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) ("Enzon") announced today that it has set Wednesday, January 27, 2010 as the date of the special meeting of stockholders to vote on the proposed sale of its specialty pharmaceutical business to the sigma-tau Group.

LecTec Corporation (OTCBB: LECT) announced today that it has issued the following open letter from Judd Berlin, the Chief Executive Officer of LecTec.

OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) today provided an update to the preliminary revenue and adjusted earnings per share growth rate guidance provided to inventors at the Company’s recent analyst R&D day meeting on December 3, 2009.

PGxHealth, a division of Clinical Data, Inc. (NASDAQ: CLDA), today announced that it has established a research collaboration with Deutsches Herzzentrum (DHZ), Munich, Germany, to evaluate the predictive value of genetic markers, including PGxHealth proprietary markers, for response to clopidogrel (Plavix®).

Poniard Pharmaceuticals (Nasdaq: PARD) today announced the sale of 3,489,728 of its common shares to Azimuth Opportunity Ltd. for net proceeds of approximately $6.5 million, or approximately $1.87 per share, under its existing committed equity financing facility with Azimuth.

PPD, Inc. (Nasdaq: PPDI) will release its fiscal year 2010 financial guidance on Tuesday, January 19, 2010, after the market closes. The release will be available on the PPD Web site at http://www.ppdi.com.

Radient Pharmaceuticals Corporation (NYSE Amex:RPC), a US-based vertically integrated pharmaceutical company, whose wholly-owned subsidiary AMDL Diagnostics, Inc. (ADI) announced today it 2010 Business Plan.

Santarus, Inc. (NASDAQ:SNTS), a specialty biopharmaceutical company, today announced that it has received the $20 million milestone payment previously announced on December 1, 2009 relating to the approval of ZEGERID OTC™ (omeprazole 20 mg/sodium bicarbonate 1100 mg capsules) under its over-the-counter (OTC) licensing agreement with Schering-Plough HealthCare Products, Inc., the consumer healthcare division of Merck & Co., Inc. Schering-Plough and Merck merged on November 3, 2009.

WuXi PharmaTech (NYSE:WX), a leading pharmaceutical, biotechnology, and medical-device research and development outsourcing company, with operations in China and the United States, announced that it had been selected for the Deloitte Technology Fast 500 Asia Pacific 2009 List, the only company in China to receive this award for the past six years.

"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus